Skip to main content

Pathology Review: Basal Cell Carcinoma (BCC) Mimickers, Immunostains and Rare Tumors

TO REGISTER: Scroll down and add to cart
ASDS Members: $49
Non-Members: $99

On Demand Course:
Registrants will have access to the course recordings through Sept. 30, 2022.

Directors:

Rajiv I. Nijhawan, MD; Ian Maher, MD
Faculty:

Divya Srivastava, MD; Sailesh Konda, MD; Daniel Knabel, MD

Description:

The purpose of this course is to review additional topics focused on pathology content areas outlined by the American Board of Dermatology (ABD) Study Guide to prepare for the MDS Subspecialty Certification Examination.

For more information about the exam being administered for the first time in Fall 2021 and eligibility visit abderm.org. The ABD was not involved in preparing the course and does not attest to whether the course is a reflection of the content of the MDS exam.

Course Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Identify histopathology of benign and malignant mimickers of basal cell carcinoma as seen on frozen sections.
  • Differentiate the various basaloid tumors encountered by the Mohs surgeon.
  • Discuss challenging cases where accurate diagnosis of benign and malignant basaloid tumors leads to precise and efficient tumor extirpation while minimizing morbidity.
  • Interpret frozen sections with MART‐1 stains for melanoma.
  • Recognize unique pathology specimen and histology of rare skin malignancies.
  • Review the use of Immunohistochemistry in micrographic surgery.

CME:
1.00 AMA PRA Category 1 Credit™
To obtain CME credit in your ASDS Learn profile and download your CME certificate, you will need to complete the course and complete the attendee evaluation.

The American Society for Dermatologic Surgery (ASDS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ASDS designates this activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.